Document:

Exhibit 10.18

 

 

July 31,
2021 

 

Jennifer Ernst 

_______________________

_______________________

 

Dear Jennifer:

 

This letter agreement (this “Agreement”)
is entered into between Jennifer Ernst (“you”) and Tivic Health Systems, Inc., a Delaware corporation (the “Company”).
Subject to your execution hereof, this Agreement, shall become effective as of the date of the consummation of the initial public offering
of the Company’s common stock, pursuant to an effective registration statement filed pursuant to the Securities Act of 1933, as
amended (the “IPO”). This Agreement confirms the terms and conditions of your employment with the Company following
the consummation of the IPO and, following the IPO, this Agreement shall supersede all prior negotiations, representations or agreements
between you and the Company, including any prior employment agreement, understanding or offer letter between you and the Company.

 

1.            Duties
and Scope of Employment.

 

(a)            Position.
For the term of your employment under this Agreement (your “Employment”), the Company agrees to continue to employ
you in the exempt position of Chief Executive Officer. You will continue to report to the Company’s Board of Directors (the “Board”).
You will continue working out of the Company’s office in Newark, California, it also being understood that the Company may require
you to perform business travel to other locations from time to time in connection with the Company’s business. You will perform
the duties and have the responsibilities and authority customarily performed and held by an employee in your position. During your tenure
as Chief Executive Officer, you will also participate as a member of the Company’s Board. 

 

(b)           Obligations
to the Company. During the term of your Employment, you will devote your full business efforts and time to the Company. During your
Employment, you agree that you will not engage in any other employment, occupation, consulting or other business activity without the
prior written consent of the Company, nor will you engage in any other activities that conflict with your obligations to the Company.
You shall comply with the Company’s policies and rules, including those policies located in the Company’s Handbook (and applicable
State Supplement), if any, and the Employee Invention Assignment and Confidentiality Agreement (the “Confidentiality Agreement”),
as they may be in effect from time to time during your Employment.

 

(c)            Employment
at Will. Your Employment will be “at will,” meaning that either you or the Company shall be entitled to terminate your
Employment at any time and for any reason, with or without cause. Any contrary representations that may have been made to you shall be
superseded by this Agreement. This Agreement will constitute the full and complete agreement between you and the Company on the “at-will”
nature of your Employment, which may only be changed in an express written agreement signed by you and a duly authorized officer of the
Company. Except as otherwise herein expressly provided for, upon the termination of your employment, you will only be entitled to the
compensation and benefits earned and the reimbursements described in this Agreement for the period preceding the effective date of the
termination.

 

    -1-

     

    

 

2.            Compensation;
Business Expenses. 

 

(a)            Base
Wage. In this exempt position, the Company will pay you as compensation for your Employment a base salary at a gross annual rate
of $275,000, pro-rated for any partial year. Your annual base salary will be subject to review and adjustment based upon the Company’s
normal performance review practices. Your base salary will continue to be payable in accordance with the Company’s standard payroll
procedures. The annual base salary specified in this Section 2(a), together with any modifications, is referred to in this Agreement
as “Base Salary.” 

 

(b)            Incentive
Compensation. At the discretion of the Board, you will be eligible to earn a discretionary, annual end-of-year incentive bonus in
an amount of up to 40% of your Base Salary, commencing with the 2022 calendar year (payable in the first quarter, 2023). The exact amount
of the incentive bonus you may receive will be dependent on the achievement of Company milestones and profitability, and such other milestones
as the Board deems appropriate. Payment of your incentive bonus, if earned, will be paid to you as soon as practical following the end
of the calendar year, contingent upon final financial results from the prior year and Board approval of meeting performance objectives
whether plan or individual, and in any event, within 60 days therefrom. You will not earn any incentive bonus (including a prorated bonus)
if your employment terminates for any reason before December 31, for the year in question. 

 

(c)            Business
Expenses. The Company will reimburse you for your necessary and reasonable business expenses incurred in connection with your duties
hereunder upon presentation of an itemized account and appropriate supporting documentation, all in accordance with the Company’s
generally applicable policies currently in effect or to be adopted after the date hereof, as may be amended from time to time.

 

3.            Employee
Benefits. You will be entitled to earn three (3) weeks of Paid Time Off (“PTO”) in accordance with the Company’s
PTO policy. You will remain eligible to participate in the employee benefit plans maintained by the Company and generally available to
similarly situated employees of the Company, subject in each case to the generally applicable terms and conditions of the plan in question
and to the determinations of any person or committee administering such plans. These benefits may change from time to time.

 

4.            Termination
of this Agreement; Separation Benefits. 

 

(a)            Termination
of this Agreement. This Agreement and your employment with the Company shall terminate under any of the following conditions: (i) your
death; (ii) your Complete Disability; (iii) upon your receipt of written notice from the Company that your employment is being
terminated for Cause; (iv) upon your receipt of written notice from the Company that your employment is being terminated other than
for Cause; (v) upon sixty (60) days’ written notice by you that you are resigning from your employment with the Company; (vi) upon
sixty (60) days’ written notice by you that you are resigning from your employment with the Company for Good Reason.

 

(b)            Separation
Benefits. You will be entitled to receive separation benefits upon termination of employment only as set forth in Section 4(b)(iv) hereof;
provided, however, that in the event you are entitled to any severance pay under a Company-sponsored severance pay plan, any such severance
pay to which you are entitled under such severance pay plan will reduce the amount of severance pay to which you are entitled pursuant
to Section 4(b)(iv) hereof. In all cases, upon termination of employment you will receive in a lump sum payment for all salary,
earned bonus (if any), and unused PTO accrued as of the date of your termination of employment.

 

    -2-

     

    

 

(i)            Voluntary
Resignation. If you voluntarily elect to terminate your employment with the Company (other than in the event of a termination by
you for Good Reason), you will not be entitled to any separation benefits. 

 

(ii)            Termination
for Cause. If the Company or any successor in interest terminates your employment for Cause (as defined below), you will not be entitled
to receive any separation benefits.

 

(iii)            Termination
for Death or Complete Disability. If your employment with the Company is terminated as a result of your death or Complete Disability,
you will not be entitled to receive any separation benefits. 

 

(iv)            Involuntary
Termination. Subject to the provisions of Section 4(b)(iv) and Section 5 hereof, if there is an Involuntary Termination
you will be entitled to receive the following: 

 

(A)            Severance
Payment. The Company will pay you an amount equal to one-twelfth (1/12th) of your Base Salary for six (6) months,
payable in accordance with the Company’s standard payroll procedures over the Severance Period. 

 

(B)            Health
Insurance. Provided that you timely elect such coverage, the Company shall pay your group health continuation coverage under the
Consolidated Omnibus Budget Reconciliation Act of 1986 (“COBRA”) during the Severance Period; provided, however, that
in the event that you become eligible for group insurance coverage in connection with new employment, such COBRA premium payments by
the Company shall terminate immediately and, in furtherance thereof, you represent, warrant, covenant and agree to promptly, and in any
event, within seven (7) days therefrom, notify the Company of your new employment and eligibility for group insurance coverage related
thereto.

 

(c)            Definitions. 

 

(i)            “Cause”
means the occurrence of any of the following: (A) your conviction for, or plea of no contest to, a felony or a crime involving moral
turpitude; (B) your commission of an act of personal dishonesty that is intended to result in your personal enrichment (excluding
inadvertent acts that are promptly cured following notice); (C) a continued material failure or failures by you to perform your lawful
and reasonable duties of employment (including, but not limited to, compliance with material written policies of the Company and material
written agreements with the Company) (but only after the Company has delivered a written demand for performance to you that describes
the basis for the Company’s belief that you have committed material violations and you have not cured within a period of 15 days
following notice); (D) your willful failure (other than due to physical incapacity) to reasonably cooperate with any audit or investigation
by a governmental authority or the Company of the Company’s business or financial conditions or practices that continues after written
notice from the Board and at least fifteen (15) days to cure; (E) it is determined that you have conducted yourself in an unprofessional,
unethical, illegal or fraudulent manner, or have acted in a manner detrimental to the reputation, character or standing of the Company,
or to the financial condition of the Company, including, but not limited to theft or misappropriation of Company’s assets, engaging
in unlawful discriminatory or harassing conduct, working while under the influence of alcohol or illegal drugs, or the filing of false
expense or related reports; (G) a material breach of any of your fiduciary duties to the Company; (H) any willful, material
violation by you of any law or regulation applicable to the business of the Company; or (I) a material breach of any of the covenants,
representations and warranties contained herein.

 

    -3-

     

    

 

(ii)            “Change
in Control” shall have the meaning as set forth in the Company's 2017 Equity Incentive Plan; provided, however, that from and
after the closing of the IPO, “Change in Control” shall have the meaning as set forth in the Company’s equity incentive
or other similar plan adopted in connection with the closing of the IPO, as may be amended from time to time.

 

(iii)            “Complete
Disability” shall mean your inability to perform your duties under this Agreement, whether with or without reasonable accommodation,
by reason of any incapacity, physical or mental, which the Company, based upon medical advice or an opinion provided by a licensed physician
acceptable to the Company, determines to have incapacitated you from satisfactorily performing all of your usual services for the Company,
with or without reasonable accommodation, for a period of at least one hundred eighty (180) days during any twelve (12) month period
(whether or not consecutive). Based upon such medical advice or opinion, the determination of the Company shall be final and binding
and the date such determination is made shall be the date of such Complete Disability for purposes of this Agreement.

 

(iv)            “Good
Reason” means the occurrence of one or more of the following (through a single action or series of actions) without your written
consent: (A) the assignment to you of any authority, duties or responsibilities or the reduction of your authority, duties or responsibilities,
either of which results in a material diminution in your authority, duties or responsibilities at the Company, unless you are provided
with a comparable position (i.e., a position of equal or greater organizational level, duties, authority and status); (B) a material
reduction by the Company in your Base Salary, other than a one-time reduction that is applicable to substantially all other similarly-situated
executives; or (C) a non-temporary relocation of your principal work location office to a location that increases your one way commute
from your principal residence by more than 50 miles. 

 

An event or action will not constitute Good Reason
unless (1) you give the Company written notice within 60 days after you know or should know of the initial existence of such event
or action, (2) such event or action is not reversed, remedied or cured, as the case may be, by the Company as soon as possible but
in no event later than 30 days of receiving such written notice from you, and (3) you terminate employment within 60 days following
the end of the cure period.

 

(v)            “Involuntary
Termination” means a termination of your employment by the Company without Cause or you terminate your employment with the
Company for Good Reason. 

 

5.            Conditions
to Receipt of Severance or other Benefits Pursuant to this Agreement.

 

(a)            Release
of Claims Agreement. Notwithstanding anything herein contained to the contrary, in order for you to receive any severance or other
benefits pursuant to Section 4(b) of this Agreement (the “Severance Benefits”), you will be required to sign
and not revoke a separation and release of claims agreement in a form reasonably satisfactory to the Company (the “Release”).
In all cases, the Release must become effective and irrevocable no later than the 60th day following your Involuntary Termination (the
 “Release Deadline Date”). If the Release does not become effective and irrevocable by the Release Deadline Date, you
will forfeit any right to the Severance Benefits. In no event will the Severance Benefits be paid or provided until the Release becomes
effective and irrevocable.

 

    -4-

     

    

 

(b)            Section 409A. 

 

(i)            Notwithstanding
anything to the contrary in this Agreement, no Severance Benefits to be paid or provided to you, if any hereunder that, when considered
together with any other severance payments or separation benefits, are considered deferred compensation under Section 409A of the
Internal Revenue Code of 1986, as amended (the “Code”), and the final regulations and any guidance promulgated thereunder
(“Section 409A”) (together, the “Deferred Payments”) will be paid or provided until you have
a “separation from service” within the meaning of Section 409A. Similarly, no Severance Benefits payable to you, if
any, under this Agreement that otherwise would be exempt from Section 409A pursuant to Treasury Regulation Section 1.409A-1(b)(9) will
be payable until you have a “separation from service” within the meaning of Section 409A.

 

(ii)            It
is intended that none of the Severance Benefits will constitute Deferred Payments but rather will be exempt from Section 409A as
a payment that would fall within the “short-term deferral period” as described in Section 5(b)(iii) below or resulting
from an involuntary separation from service as described in Section 5(b)(iv) below. In no event will you have discretion to
determine the taxable year of payment of any Deferred Payment.

 

(iii)            Notwithstanding
anything to the contrary in this Agreement, if you are a “specified employee” within the meaning of Section 409A at
the time of your separation from service (other than due to death), then the Deferred Payments, if any, that are payable within the first
6 months following your separation from service, will become payable on the date 6 months and 1 day following the date of your separation
from service. All subsequent Deferred Payments, if any, will be payable in accordance with the payment schedule applicable to each payment
or benefit. Notwithstanding anything herein to the contrary, in the event of your death following your separation from service, but before
the 6 month anniversary of the separation from service, then any payments delayed in accordance with this paragraph will be payable in
a lump sum as soon as administratively practicable after the date of your death and all other Deferred Payments will be payable in accordance
with the payment schedule applicable to each payment or benefit. Each payment and benefit payable under this Agreement is intended to
constitute a separate payment under Section 1.409A-2(b)(2) of the Treasury Regulations.

 

(iv)            Any
amount paid under this Agreement that satisfies the requirements of the “short-term deferral” rule set forth in Section 1.409A-1(b)(4) of
the Treasury Regulations will not constitute Deferred Payments for purposes of this Section 5. 

 

(v)            Any
amount paid under this Agreement that qualifies as a payment made as a result of an involuntary separation from service pursuant to Section 1.409A-
1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit will not constitute Deferred Payments
for purposes of this Section 5. 

 

(vi)            The
foregoing provisions are intended to comply with or be exempt from the requirements of Section 409A so that none of the Severance
Benefits will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so
comply or be exempt. You and the Company agree to work together in good faith to consider amendments to this Agreement and to take such
reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior
to actual payment to you under Section 409A. In no event will the Company reimburse you for any taxes that may be imposed on you
as result of Section 409A. 

 

6.            Pre-Employment
Conditions. 

 

(a)            Confidentiality
Agreement. Your acceptance of this offer and the terms of this Agreement is contingent upon the execution, and delivery to an officer
of the Company (other than you), of the Confidentiality Agreement, a copy of which is attached hereto as Attachment A for your
review and execution concurrent with the execution hereof.

 

    -5-

     

    

 

(b)            Arbitration
Agreement. In the interest of speedy resolution of disputes, new employees are required to enter into a mutual agreement to
arbitrate claims, a copy of which is attached hereto as Attachment B (the “Arbitration Agreement”) for
your review and execution concurrent with the execution hereof, and delivery to an officer of the Company (other than you). Entering
into the Arbitration Agreement is a condition of your continued employment with the Company. As set forth in more detail in the
Arbitration Agreement, you and the company agree to submit to mandatory binding arbitration any and all claims arising out of or
related to your employment with the Company and your termination thereof, including but not limited to, claims for unpaid wages,
wrongful termination, torts, stock or stock options or other ownership interest in the Company and/or discrimination (including
harassment) based upon any federal, state or local ordinance, statute, regulation or constitutional provision. THE PARTIES HEREBY
WAIVE ANY RIGHTS THEY MAY HAVE TO TRIAL BY JURY IN REGARD TO SUCH CLAIMS.

 

7.            Successors.

 

(a)            Company’s
Successors. This Agreement shall be binding upon any successor (whether direct or indirect and whether by purchase, lease, merger,
consolidation, liquidation or otherwise) to all or substantially all of the Company’s business and/or assets. For all purposes
under this Agreement, the term “Company” shall include any successor to the Company’s business or assets that
becomes bound by this Agreement. 

 

(b)            Your
Successors. This Agreement and all of your rights hereunder shall inure to the benefit of, and be enforceable by, your personal or
legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.

 

8.            Miscellaneous. 

 

(a)            Notice.
All notices and other communications contemplated under this Agreement shall be in writing and shall be deemed to have been duly given,
made and received (i) when delivered personally; (ii) two (2) days following the day when deposited with a reputable,
established overnight courier service for delivery to the intended addressee, the first of which such delivery shall have been with signature
required from the recipient; (iii) five (5) days following the day when deposited with the United States Postal Service as
first class, registered or certified mail, postage prepaid; and (iv) by confirmed electronic (email) transmission or facsimile.
In your case, mailed notices shall be addressed to you at the home address that you most recently communicated to the Company in writing.
In the case of the Company, mailed notices shall be addressed to its corporate headquarters, and all notices shall be directed to the
attention of the Board. 

 

(b)            Modifications
and Waivers. No provision of this Agreement shall be modified, waived or discharged unless the modification, waiver or discharge
is agreed to in writing and signed by you and by an authorized officer of the Company (other than you). No waiver by either party of
any breach of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered a waiver of
any other condition or provision or of the same condition or provision at another time. 

 

(c)            Whole
Agreement. No other agreements, representations or understandings (whether oral or written and whether express or implied) which
are not expressly set forth in this Agreement have been made or entered into by either party with respect to the subject matter
hereof. This Agreement, the Inventions Agreement and the Arbitration Agreement contain the entire understanding of the parties with
respect to the subject matter hereof.

 

    -6-

     

    

 

(d)            Withholding
Taxes. All payments made under this Agreement shall be subject to reduction to reflect taxes or other charges required to be withheld
by law. 

 

(e)            Choice
of Law and Severability. This Agreement shall be interpreted in accordance with the laws of the State of California without giving
effect to provisions governing the choice of law. If any provision of this Agreement becomes or is deemed invalid, illegal or unenforceable
in any applicable jurisdiction by reason of the scope, extent or duration of its coverage, then such provision shall be deemed amended
to the minimum extent necessary to conform to applicable law so as to be valid and enforceable or, if such provision cannot be so amended
without materially altering the intention of the parties, then such provision shall be stricken and the remainder of this Agreement shall
continue in full force and effect. If any provision of this Agreement is rendered illegal by any present or future statute, law, ordinance
or regulation (collectively, the “Law”) then that provision shall be curtailed or limited only to the minimum extent
necessary to bring the provision into compliance with the Law. All the other terms and provisions of this Agreement shall continue in
full force and effect without impairment or limitation.

 

(f)            No
Assignment. This Agreement and all of your rights and obligations hereunder are personal to you and may not be transferred or assigned
by you at any time.

 

(g)            Interpretation;
Construction. The headings set forth in this Agreement are for convenience of reference only and shall not be used in interpreting
this Agreement. This Agreement has been drafted by legal counsel to the Company, but you acknowledge your understanding that you have
been advised to consult with an attorney prior to executing this Agreement (and by your execution hereof, you acknowledge that you have
so consulted with an attorney of your choice or have knowingly and voluntarily waived such consultation), and the normal rule of
construction to the effect that any ambiguities are to be resolved against the drafting party will not be employed in the interpretation
of this Agreement.

 

(h)            Representations
and Warranties. You represent and warrant that you are not restricted or prohibited, contractually or otherwise, from entering into
and performing each of the terms and covenants contained in this Agreement, and that your execution and performance of this Agreement
will not violate or breach any other agreements between you and any other person or entity. You further represent and warrant that you
will not, during the term hereof, enter into any oral or written agreement in conflict with any of the provisions of this Agreement,
the agreements referenced herein and the Company’s policies. 

 

(i)            Return
of Company Property. Upon termination of this Agreement or earlier as requested by the Company, you shall deliver to the Company any
and all equipment, and, at the election of the Company, either deliver or destroy, and certify thereto, any and all drawings, notes, memoranda,
specifications, devices, formulas and documents, together with all copies, extracts and summaries thereof, and any other material containing
or disclosing any third-party information or proprietary information.

 

(j)            Counterparts.
This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic
signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

To indicate your acceptance
of the Company’s offer, please sign and date this letter in the space provided below and return it to me, along with a signed and
dated original copy of the Confidentiality Agreement and Arbitration Agreement, on or before August 2, 2021. To the extent that the
Company has not received the executed counterpart signature pages hereto and thereto on or before such date and time, this offer
shall be deemed withdrawn and shall expire.

 

    -7-

     

    

 

Very truly yours, 

 

Tivic Health Systems, Inc.

 

	By:	/s/ Karen Drexler	 

Name: Karen Drexler, Director 

 

ACCEPTED AND AGREED: 

 

Jennifer Ernst 

 

	 	/s/ Jennifer Ernst	 

Signature 

 

	Date:	07/31/2021	 

 

    -8-

     

    

 

ATTACHMENT A

 

EMPLOYEE INVENTION ASSIGNMENT AND

CONFIDENTIALITY AGREEMENT

 

(Attached)

 

    -9-

     

    

 

ATTACHMENT B 

 

ARBITRATION AGREEMENT 

 

(Attached) 

 

    -10-Exhibit 10.19

 

AMENDMENT
Agreement

 

This Amendment Agreement
(this “Amendment”) is made and entered into effective as of ____________, 2021 by and among Tivic Health
Systems, Inc., a Delaware corporation (the “Company”), and the parties who are signatories hereto
(the “Investors”).

 

Recitals

 

A.        The
Company and certain investors (including the Investors) have entered into a Note Purchase Agreement, dated as of June 17, 2020 (the
“Note Purchase Agreement”), pursuant to which the Company issued unsecured convertible promissory notes (each
a “Note,” and collectively the “Bridge Notes”) to certain investors.

 

B.         Section 13
of each of the Bridge Notes provides that, subject to limited exceptions, the Note may be amended, together with all other Bridge Notes,
by agreement of the Company and holders of Bridge Notes representing a majority of the aggregate principal amount of all of the then outstanding
Bridge Notes (collectively, the “Requisite Holders”), so long as such amendment and/or waivers are applicable
to all Bridge Notes. The undersigned Investors constitute the Requisite Holders.

 

C.         The
Company and the undersigned Investors desire to amend the Bridge Notes as herein set forth.

 

Agreement

 

NOW, THEREFORE, in consideration
of the foregoing premises and the mutual covenants and conditions set forth below, and for other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the parties to this Amendment hereby agree as follows:

 

1.          Amendment
of Section 1 of the Note. Section 1 of the Note is hereby amended and restated in its entirety and shall read as follows:

 

“1.           Definitions.
For purposes of this Note, capitalized terms used herein but not otherwise defined herein shall have the meaning set forth in this Section 1:

 

1.1         “Business
Day” means any day which is not a Saturday or Sunday or a legal holiday on which banks are authorized or required to be closed
in California.

 

1.2         “Cap”
means an amount of $40,000,000.

 

1.3         “Change
in Control” means, unless otherwise determined by the Company and the holders of at least a majority of the aggregate Principal
Amount of all of the then issued and outstanding Bridge Notes:

 

(a)      The
direct or indirect sale or transfer, in a single transaction or a series of related transactions, by the shareholders of the Company
of voting securities, in which the holders of the outstanding voting securities of the Company immediately prior to such transaction
or series of transactions hold, as a result of holding Company securities prior to such transaction, in the aggregate, securities possessing
less than fifty percent (50%) of the total combined voting power of all outstanding voting securities of the Company or of the acquiring
entity immediately after such transaction or series of related transactions;

 

(b)        A
merger or consolidation in which the Company is not the surviving entity, except for a transaction in which the holders of the outstanding
voting securities of the Company immediately prior to such merger or consolidation hold as a result of holding Company securities prior
to such transaction, in the aggregate, securities possessing more than fifty percent (50%) of the total combined voting power of all outstanding
voting securities of the surviving entity (or the parent of the surviving entity) immediately after such merger or consolidation;

 

     

     

    

 

(c)        A
reverse merger in which the Company is the surviving entity but in which the holders of the outstanding voting securities of the Company
immediately prior to such merger hold as a result of holding Company securities prior to such transaction, in the aggregate, securities
possessing less than fifty percent (50%) of the total combined voting power of all outstanding voting securities of the Company or of
the acquiring entity immediately after such merger; or

 

(d)      The
sale, transfer or other disposition (in one transaction or a series of related transactions) of all or substantially all of the assets
of the Company, except for a transaction in which the holders of the outstanding voting securities of the Company immediately prior to
such transaction(s) receive as a distribution with respect to securities of the Company, in the aggregate, securities possessing
more than fifty percent (50%) of the total combined voting power of all outstanding voting securities of the acquiring entity immediately
after such transaction(s), provided however, that the term “Change in Control” shall not include, for the purposes of this
Note, (A) a merger of the Company effected exclusively for the purpose of changing the domicile of the Company, or (B) the transfer
of more than fifty percent (50%) of the total combined voting power of all outstanding voting securities in an equity financing for bona
fide capital raising purposes.

 

1.4         “Common
Stock” means the Common Stock of the Company.

 

1.5        “Conversion”
means any conversion of this Note in connection with a Qualified Financing, Change in Control, Mandatory Conversion or IPO Conversion,
as the case may be, in accordance with the provisions hereof.

 

1.6         “Convertible
Securities” means evidences of convertible indebtedness, shares of Preferred Stock of the Company, or other securities or instruments
(other than Options) which are, directly or indirectly, convertible into or exchangeable for shares of Common Stock, either immediately
or upon the arrival of a specified date or the occurrence of a specified event.

 

1.7         “Fully
Diluted Basis” means the sum of (i) the total number of shares of Common Stock issued and outstanding immediately prior
to the applicable Conversion, and (ii) the total number of shares of Common Stock issuable, directly or indirectly, upon conversion
of all outstanding Options and Convertible Securities (other than the Bridge Notes and other Convertible Securities that will convert
into Qualified Securities, Shadow Preferred or Preferred Conversion Stock, as the case may be, in connection with a Conversion), and (iii) shares
of Common Stock reserved and available for future grant under the Company’s equity incentive or similar plans, in each case, immediately
prior to such Conversion.

 

1.8         “IPO”
means the Company’s first underwritten public offering of its Common Stock under the Securities Act of 1933, as amended.

 

1.9         “IPO
Conversion Price” shall mean a conversion price per share equal to the lesser of (x) seventy-five percent (75%) of the
per share public offering price stated on the front cover of the final prospectus for the IPO (before deduction of any underwriting commissions,
expenses or other amounts), and (y) the quotient resulting from dividing (A) the Cap, by (B) the Company’s capitalization
on a Fully Diluted Basis, as of immediately prior to the IPO Closing Date.

 

    2 

     

    

 

1.10       “Options”
means any rights, warrants, options or similar rights to subscribe for or to purchase Common Stock or Convertible Securities, whether
vested or unvested.

 

1.11       “Preferred
Conversion Price” means a price per share of Preferred Conversion Stock of $1.4034, as adjusted for as adjusted for any stock
splits, stock dividends, combinations, subdivisions, recapitalizations or the like.

 

1.12      “Preferred
Conversion Stock” means, at the election of the Company, Series Seed-1 Preferred or a newly designated series of Preferred
Stock that has substantially the same rights, preferences and privileges as the Series Seed-1 Preferred.

 

1.13       “Qualified
Financing” means the closing of an equity financing undertaken by the Company after the date hereof and before the Maturity
Date, principally for capital raising purposes, in which the aggregate amount of gross proceeds (not including cancellation of the indebtedness
represented by all Bridge Notes and other Convertible Securities that will convert into shares of Qualified Securities or Shadow Preferred,
as the case may be, in connection with such Conversion) received by the Company from the sale of any series of its equity securities totals
at least $2,000,000 in the aggregate.

 

1.14      “Qualified
Securities” means the securities sold by the Company, and purchased by investors, in a Qualified Financing (other than Shadow
Preferred).

 

1.15      “Series Seed-1
Preferred” means the shares of Series Seed-1 Preferred stock of the Company.

 

1.16      “Series Seed
Transaction Documents” means, collectively (i) the Series Seed-1, Seed-2, Seed-3 and Seed-4 Preferred Stock Investment
Agreement, dated as of July 17, 2019, by and among the Company and the investors who are a party thereto, and (ii) the Voting
Agreement, dated as of July 17, 2019, by and among the Company and the investors who are a party thereto.

 

1.17       “Shadow
Preferred” means the shares of a series of Preferred Stock issued to Holder and the holders of the other Bridge Notes in the
Qualified Financing, having identical rights, privileges, preferences and restrictions as the shares of Qualified Securities, other than
with respect to: (i) the per share liquidation preference and the conversion price for purposes of price-based anti-dilution protection,
which will equal the applicable conversion price determined to effect a Conversion of this Note in accordance with the provisions hereof;
and (ii) the basis used to determine any dividend rights, which shall be the same percentage of the conversion price determined to
effect a Conversion of this Note in accordance with the provisions hereof as applied to determine the per share dividend rights of purchasers
of Qualified Securities, relative the purchase price paid by the purchasers thereof.

 

1.18        “Transaction
Documents” means the Note Purchase Agreement and the Bridge Notes.”

 

2.         Amendment
of Section 7 of the Note. Section 7 of the Note is hereby amended and restated in its entirety and shall read as follows:

 

“7.           Conversion
at Maturity Date; IPO.

 

7.1         Maturity
Date Conversion. In the event that neither a Qualified Financing nor a Change in Control shall have occurred on or before the Maturity
Date then, notwithstanding anything herein contained to the contrary, the outstanding Principal Amount and all accrued but unpaid interest
thereon as of the Maturity Date shall be automatically converted into shares of Preferred Conversion Stock as of the Maturity Date (the
 “Mandatory Conversion”). The number of shares (which will be rounded down to the closest whole number) of Preferred
Conversion Stock to be issued upon such conversion shall be equal to the quotient obtained by dividing (x) the outstanding Principal
Amount and all accrued but unpaid interest thereon immediately prior to the Maturity Date, by (y) the Preferred Conversion Price.

 

    3 

     

    

 

7.2        Ancillary
Agreements. In connection with the Mandatory Conversion, Holder agrees to execute and deliver to the Company the Series Seed
Transaction Documents and/or any documents reasonably requested by the Company, including without limitation, a stock purchase agreement,
an investors’ rights agreement, a right of first refusal and co-sale agreement and a voting agreement, thereby agreeing to be bound
by all obligations and receive all rights thereunder.

 

7.3         IPO
Conversion. In the event that the Company shall consummate an IPO prior to a Qualified Financing, a Change in Control or the Maturity
Date, then, notwithstanding anything herein contained to the contrary, the outstanding Principal Amount and, at the election of the Company
all accrued but unpaid interest thereon to the date of conversion pursuant to this Section 7.3, shall be automatically converted
into shares of Common Stock as of immediately prior to the consummation of an IPO (the “IPO Closing Date”), at a per
share price equal to the IPO Conversion Price (the “IPO Conversion”). The number of shares (which will be rounded
down to the closest whole number) of Common Stock to be issued upon such conversion shall be equal to the quotient obtained by dividing
(x) the outstanding the outstanding Principal Amount and, at the election of the Company, all accrued but unpaid interest thereon
(calculated through the date that is not more than seven (7) days prior to the IPO Closing Date), by (y) the IPO Conversion
Price. Accrued interest which is not converted into Common Stock in accordance with the provisions hereof, shall be paid to Holder as
soon as practicable following the IPO Conversion.

 

7.4         IPO
Ancillary Agreements. In connection with the IPO Conversion, Holder agrees to execute and deliver to the Company such documents and
agreements as may be reasonably be requested by the Company and/or its underwriter, including, without limitation, a lockup agreement.”

 

3.         Miscellaneous.

 

(a)         Governing
Law; Jurisdiction; Attorney Fees. The parties hereto agree that this Amendment will be governed by and construed under the internal
laws of the State of California, as applicable to agreements made and to be performed in such state, without regard to principles of
conflicts of law. The parties hereto agree that any dispute arising in connection with the interpretation or validity of, or otherwise
arising out of, this Amendment, will be subject to the exclusive jurisdiction of the California State and Federal Courts in and for Santa
Clara County, California. The parties hereto hereby agree to submit to the personal and exclusive jurisdiction and venue of such courts
and agree that process may be served in the manner provided herein for the giving of notices or otherwise as allowed by applicable law.
Each party hereto waives any defense of inconvenient forum to the maintenance of any action so brought and waives any bond, surety, or
other security that might be required of any other party hereto with respect thereto. In the event that any action, suit or other proceeding
is instituted concerning or arising out of this Amendment or any transaction contemplated hereunder, the prevailing party shall recover
all of such party’s costs and attorneys’ fees incurred in each such action, suit or other proceeding, including any and all
appeals or petitions therefrom.

 

(b)         Headings.
The headings and captions used in this Amendment are used for convenience only and are not to be considered in construing or interpreting
this Amendment. All references in this Amendment to Sections shall, unless otherwise provided, refer to Sections hereof.

 

    4 

     

    

 

(c)         Amendments
and Waivers. No amendment or modification of this Amendment shall be deemed effective unless made in writing and signed by the Company
and the Requisite Holders.

 

(d)         Entire
Agreement. The Note Purchase Agreement and the Bridge Notes, as supplemented and modified by this Amendment, contain the entire agreement
among the parties with respect to the subject matter thereof and amend, restate and supersede all prior and contemporaneous arrangements
or understandings with respect thereto, including, without limitation, any agreement or instrument executed by and between the Company
and Investor prior to or following the date hereof.

 

(e)         Reference
to the Agreement. Upon the effectiveness of this Amendment, on and after the date hereof, each reference in the Note Purchase Agreement,
and the Bridge Notes to “this Agreement,” “this Note,” “the Bridge Notes,” “hereunder,”
 “hereof,” “herein” or words of like import, shall mean and be a reference to the Note Purchase Agreement or the
Bridge Notes, as applicable, as amended hereby and as may be further amended from time to time in accordance with the provisions thereof.

 

(f)         Severability.
To the extent that any provision of this Amendment or any paragraph, term, sentence, phrase, clause or word of this Amendment shall
be found to be void, illegal or unenforceable for any reason (and not subject to further appeal), (i) the remaining terms and
provisions hereof shall be unimpaired and shall remain in full force and effect, and (ii) the illegal, invalid or unenforceable
provision or term shall be replaced by a term or provision that is valid and enforceable and that comes closest to expressing the
intention of such invalid or unenforceable term or provision.

 

(g)         Further
Assurances. The parties to this Amendment will execute such further documents and perform such further acts as may be reasonably necessary
to carry out the intent of this Amendment.

 

(h)        Counterparts.
This Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic
signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

[Remainder of Page Left Blank Intentionally]

 

    5 

     

    

 

IN WITNESS WHEREOF, the parties
hereto have executed this Amendment Agreement as of the date set forth in the first paragraph hereof.

 

	Company:	TIVIC HEALTH SYSTEMS, INC.,
	 	a Delaware corporation
	 	 
	 	By:  	 
	 	Name: Jennifer Ernst
	 	Title: Chief Executive Officer

 

INVESTORS:

 

	If Investor is a Corporation, Partnership or Other Entity:	 	If Investor is an Individual:
	 	 	 
	Name of Entity	 	Print Name of Individual
	 	 	 
	Signature of Authorized Person	 	Signature of Individual
	 	 	 
	Print Name of Authorized Person	 	Print Name of Individual (If more than one signatory)
	 	 	 
	Title	 	Signature of Additional Individual (If more than one signatory)

 

[SIGNATURE PAGE TO AMENDMENT AGREEMENT]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}]]